Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells 10,000 Shares of Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Peter Boyd sold 10,000 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $6.30, for a total transaction of $63,000.00. Following the sale, the insider directly owned 278,323 shares of the company’s stock, valued at approximately $1,753,434.90. This represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Aquestive Therapeutics Trading Down 5.7%

AQST stock traded down $0.34 on Monday, hitting $5.65. 3,783,104 shares of the company’s stock traded hands, compared to its average volume of 1,807,882. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $6.43. The stock has a market cap of $563.42 million, a price-to-earnings ratio of -8.07 and a beta of 1.82. The stock has a fifty day moving average of $4.37 and a 200-day moving average of $3.50.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Oppenheimer boosted their price target on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Zacks Research upgraded shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 13th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Finally, Lifesci Capital upgraded shares of Aquestive Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and an average target price of $10.29.

Institutional Trading of Aquestive Therapeutics

Several large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock worth $6,545,000 after buying an additional 276,295 shares during the period. Pale Fire Capital SE boosted its holdings in shares of Aquestive Therapeutics by 25.5% during the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after buying an additional 340,767 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of Aquestive Therapeutics by 7.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock worth $3,073,000 after buying an additional 75,275 shares during the period. Sio Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 141.9% during the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock worth $3,136,000 after buying an additional 555,860 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after buying an additional 621,614 shares during the period. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.